Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Retained Earnings (2018 - 2025)

Historic Retained Earnings for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to -$2.5 billion.

  • Revolution Medicines' Retained Earnings fell 6227.05% to -$2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 billion, marking a year-over-year decrease of 6227.05%. This contributed to the annual value of -$1.7 billion for FY2024, which is 5274.58% down from last year.
  • Latest data reveals that Revolution Medicines reported Retained Earnings of -$2.5 billion as of Q3 2025, which was down 6227.05% from -$2.2 billion recorded in Q2 2025.
  • Revolution Medicines' 5-year Retained Earnings high stood at -$302.7 million for Q1 2021, and its period low was -$2.5 billion during Q3 2025.
  • Its 5-year average for Retained Earnings is -$1.1 billion, with a median of -$867.7 million in 2023.
  • In the last 5 years, Revolution Medicines' Retained Earnings plummeted by 7290.49% in 2021 and then plummeted by 5078.17% in 2023.
  • Revolution Medicines' Retained Earnings (Quarter) stood at -$452.6 million in 2021, then tumbled by 54.95% to -$701.3 million in 2022, then plummeted by 62.22% to -$1.1 billion in 2023, then crashed by 52.75% to -$1.7 billion in 2024, then plummeted by 44.1% to -$2.5 billion in 2025.
  • Its Retained Earnings stands at -$2.5 billion for Q3 2025, versus -$2.2 billion for Q2 2025 and -$2.0 billion for Q1 2025.